Updates are available Correction dated 2025-01-20
Click to view Correction: https://doi.org/10.1038/s41588-025-02090-9
-
Authors
Fong, Samson H.
Kuenzi, Brent M.
Mattson, Nicole M. https://orcid.org/0000-0001-5881-3387
Lee, John https://orcid.org/0000-0002-7967-3384
Sanchez, Kyle
Bojorquez-Gomez, Ana
Ford, Kyle
Munson, Brenton P.
Licon, Katherine
Bergendahl, Sarah
Shen, John Paul
Kreisberg, Jason F. https://orcid.org/0000-0002-3616-079X
Mali, Prashant https://orcid.org/0000-0002-3383-1287
Hager, Jeffrey H.
White, Michael A.
Ideker, Trey https://orcid.org/0000-0002-1708-8454
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (CA243885, CA212456)
- License Information
-
More Information
Article History
Received: 19 September 2023
Accepted: 2 October 2024
First Online: 18 November 2024
Change Date: 20 January 2025
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41588-025-02090-9
Competing interests
: J.H.H. and M.A.W. are former or current employees of Ideaya Biosciences and have an equity interest. T.I. is a member of the Ideaya Biosciences scientific advisory board and has an equity interest. T.I. is also a co-founder and member of the advisory board and has an equity interest in Data4Cure and Serinus Biosciences. The terms of these arrangements have been reviewed and approved by the UCSD in accordance with its conflict-of-interest policies. B.M.K. is an employee of Vividion Therapeutics and has equity interests in Pfizer and Vividion Therapeutics. The other authors declare no competing interests.
